SARS-CoV-2 Omicron has similar infectious viral load to Delta

NewsGuard 100/100 Score

In a recent study published on the medRxiv* preprint server, researchers compare severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pre-variants of concern (VOC) strains and the Delta VOC strain. To do this, the researchers compared ribonucleic acid (RNA) and infectious viral load (VL) in non-vaccinated individuals, as well as in vaccination breakthrough infections caused by the SARS-CoV-2 Delta and Omicron variants.

Study: Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta, and Omicron. Image Credit: Dotted Yeti / Shutterstock.com

Study: Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta, and Omicron. Image Credit: Dotted Yeti / Shutterstock.com

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

VL influences SARS-CoV-2 secondary transmission. Higher VL has been attributed, at least in part, to the emergence of Alpha and Delta VOCs.

Furthermore, with segments of the population having received vaccines, understanding VL in breakthrough infections post-vaccination is critical. Studies on the presence of infectious viruses by cell culture isolation are important, as RNA VL is a weak indicator for infectiousness.

About the study

In the current study, up to five days post-onset of symptoms (DPOS), the researchers examined viral load features in the upper respiratory tract (URT) of unvaccinated pre-VOC-infected coronavirus disease 2019 (COVID-19) participants, as well as vaccinated and unvaccinated Delta VOC-infected COVID-19 subjects. In this cohort, 384 samples were included, with 118 samples acquired from patients infected with the pre-VOC SARS-CoV-2 and 248 from patients infected with the Delta VOC.

A total of 121 of the Delta VOC-infected patients had been vaccinated twice prior to their infection, whereas 127 had not been vaccinated. The study also included 18 vaccinated people who had recently been infected with Omicron. Using quantitative real-time PCR (qRT-PCR) and a focus-forming assay, the researchers measured genome copies and infectious viral titers in SARS-CoV-2-positive nasopharyngeal swabs.

The researchers first examined whether RNA genome copies are a good predictor of infectious viral shedding. They then determined whether infectious viral loads in patient samples were related to patient age and gender.

Over the first five symptomatic days, the researchers compared genome copies and infectious viral levels in pre-VOC and Delta VOC samples from unvaccinated patients. They further evaluated genome copies and infectious viral loads in non-vaccinated and vaccinated patients infected with the Delta VOC throughout the first five days after infection to determine whether immunization had an effect on virus shedding.

The researchers also investigated infectious viral shedding in vaccinated patients infected with the novel VOC Omicron strain after it emerged. In nasopharyngeal swab samples obtained from 18 Omicron- and 17 Delta-infected patients, RNA, and infectious viral load levels were also compared.

Study findings

The results showed that unvaccinated Delta-infected individuals had a greater infectious viral load than pre-VOC infected patients and that vaccinated patients had a much lower infectious viral load. There was no difference in infectious viral load between Delta and Omicron breakthrough cases.

RNA genome copies in URT swab samples were only weakly linked with infectious virus shedding. In fact, the researchers discovered more RNA genome copies in the swabs of unvaccinated individuals infected with pre-VOC SARS-CoV-2 strains than the Delta VOC within the first five DPOS. At the same time, Delta VOC had greater infectious viral titers.

During the first five days after symptom onset, the researchers were able to show that infectious viral load, rather than RNA genome copies, is reduced in vaccinated Delta VOC patients. Furthermore, approximately 50% of transmissions for pre-VOC SARS-CoV-2 strains occur during this time frame, thereby indicating that a reduction in viral load could significantly contribute to a lower secondary attack rate.

According to the data, the higher transmissibility of the SARS-CoV-2 Omicron variant is not associated with the shedding of a larger number of infectious viral particles in vaccinated patients with equivalent RNA viral load and infectious virus shedding.

Quantitative infectious viral loads versus overall virus isolation success.

Quantitative infectious viral loads versus overall virus isolation success.

Limitations

Only samples with cycle threshold (Ct) values less than 27 were included and were obtained within the first five DPOS, but not later. As patients with low viral loads were not included, absolute counts on RNA copies are skewed toward larger viral loads.

Furthermore, the researchers were concentrated on infectious virus shedding. To this end, it was demonstrated that SARS-CoV-2 culture is unlikely to be successful from samples with higher Ct values and that the vast majority of secondary transmission occurs before five DPOS. However, this needs to be formally assessed in Omicron cases.

The researchers also did not have access to samples from Omicron-infected unvaccinated people due to the recent emergence of this strain. Finally, the researchers indicated that almost all of the patients in this study were vaccinated with messenger ribonucleic acid (mRNA) vaccines, which produce high neutralizing antibody titers but low mucosal antibodies. As a result, the findings do not apply to other vaccines, especially those used largely in low- and middle-income countries.

RNA viral load and infectious viral titers for unvaccinated vs. vaccinated individuals infected Delta (A) Genome copies (left panel) and infectious virus (right panel) for vaccinated and unvaccinated Delta infected patients. Error bars indicate mean±SD. The t-test was used to determined differences of means. ***p=0·0005; ****p<0·0001. Genome copies (B) and infectious viral loads (C) measured for vaccinated and unvaccinated Delta infected patients at different dpos. The solid lines represent the fitted curve calculated using (locally estimated scatterplot smoothing) LOESS method.

RNA viral load and infectious viral titers for unvaccinated vs. vaccinated individuals infected Delta (A) Genome copies (left panel) and infectious virus (right panel) for vaccinated and unvaccinated Delta infected patients. Error bars indicate mean±SD. The t-test was used to determined differences of means. ***p=0·0005; ****p<0·0001. Genome copies (B) and infectious viral loads (C) measured for vaccinated and unvaccinated Delta infected patients at different dpos. The solid lines represent the fitted curve calculated using (locally estimated scatterplot smoothing) LOESS method.

Conclusions

Taken together, the study results show that the Delta VOC has stronger infectivity but much lower infectivity and faster virus clearance in vaccinated individuals. Furthermore, the findings demonstrated that the Omicron and Delta VOCs have identical infectious viral loads. In addition to overall virus isolation performance, measuring viral loads can also provide superior insights into viral shedding dynamics in acute SARS-CoV-2 infection.

“We observed higher RNA genome copies in pre-VOC SARS-CoV-2 compared to Delta, but significantly higher IVTs in Delta infected individuals.”

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 10 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Saurabh Chaturvedi

Written by

Saurabh Chaturvedi

Saurabh Chaturvedi is a freelance writer from Jaipur, India. He is a gold medalist in Masters in Pharmaceutical Chemistry and has extensive experience in medical writing. He is passionate about reading and enjoys watching sci-fi movies.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chaturvedi, Saurabh. (2023, May 10). SARS-CoV-2 Omicron has similar infectious viral load to Delta. News-Medical. Retrieved on April 18, 2024 from https://www.news-medical.net/news/20220116/SARS-CoV-2-Omicron-has-similar-infectious-viral-load-to-Delta.aspx.

  • MLA

    Chaturvedi, Saurabh. "SARS-CoV-2 Omicron has similar infectious viral load to Delta". News-Medical. 18 April 2024. <https://www.news-medical.net/news/20220116/SARS-CoV-2-Omicron-has-similar-infectious-viral-load-to-Delta.aspx>.

  • Chicago

    Chaturvedi, Saurabh. "SARS-CoV-2 Omicron has similar infectious viral load to Delta". News-Medical. https://www.news-medical.net/news/20220116/SARS-CoV-2-Omicron-has-similar-infectious-viral-load-to-Delta.aspx. (accessed April 18, 2024).

  • Harvard

    Chaturvedi, Saurabh. 2023. SARS-CoV-2 Omicron has similar infectious viral load to Delta. News-Medical, viewed 18 April 2024, https://www.news-medical.net/news/20220116/SARS-CoV-2-Omicron-has-similar-infectious-viral-load-to-Delta.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows slight increase in Guillain-Barre syndrome risk with adenovirus COVID vaccines